619 related articles for article (PubMed ID: 33783469)
1. Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility.
Alexander GC; Emerson S; Kesselheim AS
JAMA; 2021 May; 325(17):1717-1718. PubMed ID: 33783469
[No Abstract] [Full Text] [Related]
2. Controversial Approval of New Drug to Treat Alzheimer's Disease.
Aschenbrenner DS
Am J Nurs; 2021 Oct; 121(10):22-23. PubMed ID: 34554982
[TBL] [Abstract][Full Text] [Related]
3. What the Aducanumab Approval Reveals About Alzheimer Disease Research.
Manly JJ; Glymour MM
JAMA Neurol; 2021 Nov; 78(11):1305-1306. PubMed ID: 34605885
[No Abstract] [Full Text] [Related]
4. The Problem of Aducanumab for the Treatment of Alzheimer Disease.
Alexander GC; Karlawish J
Ann Intern Med; 2021 Sep; 174(9):1303-1304. PubMed ID: 34138642
[No Abstract] [Full Text] [Related]
5. The Failure of Solanezumab - How the FDA Saved Taxpayers Billions.
Sacks CA; Avorn J; Kesselheim AS
N Engl J Med; 2017 May; 376(18):1706-1708. PubMed ID: 28467878
[No Abstract] [Full Text] [Related]
6. Aducanumab and the Business of Alzheimer Disease-Some Choice.
Karlawish J
JAMA Neurol; 2021 Nov; 78(11):1303-1304. PubMed ID: 34410302
[No Abstract] [Full Text] [Related]
7. US Food and Drug Administration Approval of Aducanumab-Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?
Planche V; Villain N
JAMA Neurol; 2021 Nov; 78(11):1307-1308. PubMed ID: 34515750
[No Abstract] [Full Text] [Related]
8. How the US Food and Drug Administration's approval of aducanumab for Alzheimer's disease has implication for oncology and beyond.
Lythgoe MP; Prasad V
Eur J Cancer; 2021 Nov; 157():68-70. PubMed ID: 34487987
[No Abstract] [Full Text] [Related]
9. Can we learn lessons from the FDA's approval of aducanumab?
Liu KY; Howard R
Nat Rev Neurol; 2021 Nov; 17(11):715-722. PubMed ID: 34535787
[TBL] [Abstract][Full Text] [Related]
10. Revisiting FDA Approval of Aducanumab.
Alexander GC; Knopman DS; Emerson SS; Ovbiagele B; Kryscio RJ; Perlmutter JS; Kesselheim AS
N Engl J Med; 2021 Aug; 385(9):769-771. PubMed ID: 34320282
[No Abstract] [Full Text] [Related]
11. Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval?
Schulman KA; Greicius MD; Richman B
JAMA; 2021 Aug; 326(5):383-384. PubMed ID: 34279572
[No Abstract] [Full Text] [Related]
12. A Middle Ground for Accelerated Drug Approval-Lessons From Aducanumab.
Emanuel EJ
JAMA; 2021 Oct; 326(14):1367-1368. PubMed ID: 34554184
[No Abstract] [Full Text] [Related]
13. [Aducanumab approval for Alzheimer's disease in the USA: the surrender of science].
Dal-Ré R
Rev Neurol; 2021 Oct; 73(8):296-297. PubMed ID: 34617583
[TBL] [Abstract][Full Text] [Related]
14. Representativeness of Participants Eligible to Be Enrolled in Clinical Trials of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries With Alzheimer Disease and Mild Cognitive Impairment.
Anderson TS; Ayanian JZ; Souza J; Landon BE
JAMA; 2021 Oct; 326(16):1627-1629. PubMed ID: 34499725
[TBL] [Abstract][Full Text] [Related]
15. Does the FDA-approved Alzheimer drug aducanumab have a place in the Australian pharmacopoeia?
Gleason A; Ayton S; Bush AI
Med J Aust; 2022 Mar; 216(4):172-174. PubMed ID: 35141902
[No Abstract] [Full Text] [Related]
16. Of education and public policy: Aducanumab.
Lundebjerg NE; Hollmann PA; Supiano MA
J Am Geriatr Soc; 2022 Jan; 70(1):81-84. PubMed ID: 34674219
[No Abstract] [Full Text] [Related]
17. A carte blanche approval in Alzheimer's.
Nat Biotechnol; 2021 Jul; 39(7):781. PubMed ID: 34183862
[No Abstract] [Full Text] [Related]
18. Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab.
Rabinovici GD
N Engl J Med; 2021 Aug; 385(9):771-774. PubMed ID: 34320284
[No Abstract] [Full Text] [Related]
19. Accelerated Approval of Aducanumab: Where Do We Stand Now?
Barenholtz Levy H
Ann Pharmacother; 2022 Jun; 56(6):736-739. PubMed ID: 34595939
[TBL] [Abstract][Full Text] [Related]
20. Update: FDA approval of Biogen's aducanumab.
Hollmann P
Geriatr Nurs; 2022; 43():318-319. PubMed ID: 34996638
[No Abstract] [Full Text] [Related]
[Next] [New Search]
